Deaddiction drugs to
generate $2.3 bn by 2010
May 31, 2007
According to a new study released by Kalorama Information, titled “Smoking Cessation and Addiction Treatments: A World Market Analysis”, global sales of smoking cessation and addiction treatments are expected to shot up from $1.1 billion in 2005 to more than $2.3 billion in 2010.
The newly released report includes data for nicotine addiction, drug addiction, and alcohol abuse; current and forecasted revenues through 2010; current and forecasted market share with consideration of new players in the market; reviews of current products and new products in the pipeline; and key trends driving pharmaceutical treatments for smoking cessation and drug/alcohol addiction.
As per the report, nicotine is used by over 1.4 billion people out of which 50 million are from the U.S. while the awareness being spread by most of the countries to stop smoking has fuelled the growth of this segment of the pharmaceutical industry.
This segment of the pharma industry is likely to see some dramatic changes with entry of Pfizer into the smoking cessation drug segment. As of now, this segment of the market is dominated by GlaxoSmithKline (with its product called Zyban), and Schering-Plough / Reckitt Benckiser ( product-Suboxone/Subetex substance abuse treatment).
Melissa Elder, the author of the report, said that Pfizer's, with its smoking cessation drug called Chantix, will grab the largest chunk of the market share. |
